Curanex Pharmaceuticals Inc regained compliance with Nasdaq Listing Rule 5550(a)(2) regarding the minimum bid price requirement. The company previously received a deficiency notice on November 5, 2025, for failing to maintain a $1.00 per share closing price for 30 consecutive business days. To address this, Curanex effected a 1-for-20 reverse stock split of its common shares on August 20, 2026. On September 3, 2026, Nasdaq notified the company that its stock had closed at $1.00 or greater for the last 10 consecutive business days following the split, resolving the compliance issue. Curanex Pharmaceuticals Inc operates in the biotechnology industry and focuses on drug discovery and development.

Curanex Pharmaceuticals Inc filed a Certificate of Amendment with the Nevada Secretary of State to implement a 1-for-20 reverse stock split. The action became effective at 12:01 a.m. Pacific Time on August 20, 2026. This corporate action converts every 20 outstanding shares into one share, reducing the total issued and outstanding common stock from approximately 31,364,812 to roughly 1,568,241 shares. The company intends for its Common Stock to begin trading on a reverse split-adjusted basis under the symbol CURX on August 20, 2026. This move aims to regain compliance with Nasdaq's $1.00 minimum bid price requirement. Curanex Pharmaceuticals Inc operates in the biopharmaceutical industry, focusing on drug discovery and development.